Both continuous and pulse treatments with MLN4924 suppress NF-κB activity in CLL B-cells ex vivo, and alkylating agents bendamustine and chlorambucil amplify MLN4924-induced DNA damage and apoptosis thereby improving therapeutic efficacy [90–92]. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.